SCHEMBL1027884

SCHEMBL1027884

Cc1ccc(CCN(C(=O)O)C(C)(C)C)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
HTT P42858 1/20 0.47
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
FFAR1 O14842 2/20 0.42
TDP1 Q9NUW8 1/20 0.42
CNR2 P34972 2/20 0.41
LTB4R Q15722 1/20 0.40
LTB4R2 Q9NPC1 1/20 0.40
LMNA P02545 2/20 0.39
ALDH1A1 P00352 1/20 0.39
HPGD P15428 1/20 0.39
CYP1A2 P05177 1/20 0.38
CYP2A6 P11509 1/20 0.38
TAAR1 Q96RJ0 1/20 0.38
KCNH2 Q12809 1/20 0.38
PLAAT3 P53816 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2881402 0.86 PPARA (0.49) MEN1KMT2AL3MBTL1HTTNPC1
SCHEMBL1935310 0.86 MEN1 (0.47) MEN1KMT2AL3MBTL1HTTNPC1
SCHEMBL4147783 0.86 ESRRG (0.49) MEN1KMT2AL3MBTL1HTTLMNA
SCHEMBL21247482 0.86 KMT2A (0.63) MEN1KMT2AL3MBTL1HTTNPC1
SCHEMBL1935745 0.85 MEN1 (0.46) MEN1KMT2AL3MBTL1HTTNPC1
SCHEMBL11898599 0.85 MEN1 (0.46) MEN1KMT2AL3MBTL1HTTNPC1
SCHEMBL2575721 0.85 TAAR1 (0.50) MEN1KMT2AL3MBTL1HTTFFAR1
SCHEMBL21997106 0.85 KMT2A (0.46) MEN1KMT2AL3MBTL1HTTSMN1; SMN2
SCHEMBL1845384 0.85 MEN1 (0.46) MEN1KMT2AL3MBTL1HTTNPC1
SCHEMBL1936801 0.82 KMT2A (0.48) MEN1KMT2AL3MBTL1HTTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3452485-A2 ARGINASE INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS Oncoarendi Therapeutics SA (PL) 2019-03-13 EP disclosed
WO-2017191130-A2 ARGINASE INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS ONCOARENDI THERAPEUTICS SA (PL) 2017-11-09 WO disclosed
US-8513235-B2 Homocysteine synthase inhibitor MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-08-20 US disclosed
US-20110034440-A1 HOMOCYSTEINE SYNTHASE INHIBITOR MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-02-10 US disclosed
EP-2275404-A1 HOMOCYSTEINE SYNTHASE INHIBITOR Mitsubishi Tanabe Pharma Corporation (JP) 2011-01-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110034440-A1 HOMOCYSTEINE SYNTHASE INHIBITOR BHMT, CBS, BHMT2 MEN1 514/4885KMT2A 1006/4885L3MBTL1 1505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.